INCY Incyte Corporation - Common Stock
$125,49
Preço · Ago 19, 2026
Fundamentais a partir de Jul 28, 2026
Intervalo 52 Semanas
$81–$133
86% of range
Classificação do Analista
HOLD
33 analysts
Preço-Alvo
$125
P/E (TTM)
19.6
ROE
27.6%
Margem de Lucro Líquido
25.0%
Sobre Incyte Corporation - Common Stock Visão geral da empresa da Wikipedia
Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.
Ler mais
Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.
Incyte Corporation currently develops and manufactures prescription biopharmaceutical medications in multiple therapeutic areas including oncology, inflammation, and autoimmunity.
History
Incyte Corporation was founded by Roy A. Whitfield on April 8, 1991, in Palo Alto, California, as a genomics company. It became a public company in 1993. Subsequently, scientists and chemists were recruited from DuPont to work for Incyte. Incyte moved its headquarters to Delaware, and acquired Maxia Pharmaceuticals in 2003.
In November 2013, Incyte announced its relocation to new headquarters in Wilmington, Delaware, completing the move by the end of 2014. Hervé Hoppenot became CEO in January 2014.
In 2017, the company became part of the S&P 500 Index, which tracks the 500 most widely held U.S. stocks.
In 2015, Incyte established its European headquarters in Geneva, Switzerland, and later moved this headquarters in 2021. The company expanded its Delaware headquarters, including the addition of a research and development facility, in 2022. Incyte acquired Villaris Therapeutics in 2022, and Escient Pharmaceuticals in 2024.
For 2025, the company reported $5.141 billion in revenue, $6.957 billion in assets and $1.286 billion in net income. Incyte is publicly traded on the NASDAQ under the symbol INCY. Incyte now operates out of North America, Asia, and Europe. Bill Meury became CEO in 2025. Meury replaced Hoppenot, who retired after 11 years in the position.
Pharmaceuticals
Incyte Corporation currently has seven marketed and co-marketed pharmaceutical products, including Jakafi (ruxolitinib), Pemazyre (pemigatinib), Monjuvi (tafasitamab-cxix), Opzelura (Ruxolitinib), Tabrecta (capmatinib), Olumiant (Baricitinib), and Iclusig (ponatinib).
In 2013, Novartis acquired Incyte's c-Met inhibitor capmatinib (INC280, INCB028060), which is marketed under the brand name Tabrecta.
As of 2014, the company was developing baricitinib, an oral JAK1 and JAK2 inhibitor drug for rheumatoid arthritis in partnership with Eli Lilly. It gained EU approval in February 2017. In April 2017, the US FDA issued a rejection, citing concerns about dosing and safety. In May 2018, baricitinib was approved in the United States for the treatment of rheumatoid arthritis under the brand name Olumiant.
As of 2016 epacadostat, an indoleamine 2,3-dioxygenase (IDO1) inhibitor, was in development for various cancers and was in combination trials with Merck's pembrolizumab (Keytruda) and Bristol Myers Squibb's nivolumab (Opdivo).
Acquisition history
Incyte has made a total of 3 acquisitions.
Maxia Pharmaceuticals (2003): An early acquisition in Incyte's history, the company purchased Maxia in 2003 for $42 million.
Villaris Therapeutics (2022): This acquisition was valued at approximately $1.4 billion and included an upfront payment along with milestones. It added new assets to Incyte's portfolio for treating vitiligo and other autoimmune conditions.
Escient Pharmaceuticals (2024): In May 2024, Incyte acquired this San Diego-based, clinical-stage company for $750 million. The acquisition provided Incyte with two oral drug candidates for inflammatory diseases, EP262 and EP547.
Fonte: Wikipedia (Inglês), CC BY-SA 4.0 · Ver na Wikipedia ↗
INCY Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas
Preço
$125.48
Capitalização de Mercado
$24.90B
P/E (TTM)
19.6
EPS (TTM)
$6.41
Receita (TTM)
$5.14B
Rendimento div.
—
ROE
27.6%
Dívida/Capital
—
Intervalo 52 Semanas
$81 – $133
INCY Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização
Configure
Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS
Receita e Lucro Líquido
$5.14B
2016-12-31
→
2025-12-31
EPS
$6.41
2016-12-31
→
2025-12-31
Fluxo de caixa livre
—
2017-12-31
→
2022-12-31
Margens
25.0%
Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?
Métrica
Tendência de 5 anos
INCY
Mediana de Pares
P/E (TTM)
19.6
17.7
P/S (TTM)
4.8
6.8
P/B
4.8
6.4
Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC
Métrica
Tendência de 5 anos
INCY
Mediana de Pares
Operating Margin (Margem Operacional)
29.5%
—
Net Profit Margin (Margem de Lucro Líquido)
25.0%
20.3%
ROA
20.8%
11.4%
ROE
27.6%
16.8%
ROIC
22.7%
—
Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial
Métrica
Tendência de 5 anos
INCY
Mediana de Pares
Current Ratio (Índice de liquidez corrente)
3.3
3.4
Quick Ratio (Índice de Liquidez Seca)
2.0
—
Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos
Métrica
Tendência de 5 anos
INCY
Mediana de Pares
Revenue YoY (Receita Ano a Ano)
21.2%
—
Revenue CAGR 3Y (CAGR Receita 3A)
14.8%
—
Revenue CAGR 5Y (CAGR Receita 5A)
14.0%
—
EPS YoY
4173.3%
—
Net Income YoY (Lucro Líquido Ano a Ano)
3845.0%
—
Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber
Métrica
Tendência de 5 anos
INCY
Mediana de Pares
INCY Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta
COMPRA
33 analistas
- Compra forte 8 24,2%
- Compra 9 27,3%
- Manter 16 48,5%
- Venda 0 0,0%
- Venda forte 0 0,0%
Preço-alvo de 12 meses
23 analistas · 2026-08-18
Mediana
$120.00
Agora
$125.48
Mín
$86.00
Máx
$155.00
Alvo mediano
$120.00
-4,4%
Alvo médio
$125.17
-0,2%
Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados
Surpresa Média
0.33%
| Período | EPS Actual | EPS est. | Surpresa |
|---|---|---|---|
| 30 de Junho de 2026 | $3.09 | $2.14 | 0.95% |
| 31 de Março de 2026 | $1.81 | $1.40 | 0.41% |
| 31 de Dezembro de 2025 | $1.80 | $1.97 | -0.17% |
| 30 de Setembro de 2025 | $2.26 | $1.69 | 0.57% |
| 30 de Junho de 2025 | $1.57 | $1.50 | 0.07% |
| 31 de Março de 2025 | $1.16 | $1.04 | 0.12% |
Comparação de pares (subindústria GICS) Métricas chave vs pares do setor
| Ticker | Capitalização de Mercado | P/E | Receita YoY | Margem Líquida | ROE | Margem Bruta |
|---|---|---|---|---|---|---|
| INCY | $19.60B | 15.4 | 21.2% | 25.0% | 27.6% | — |
| RVMD | — | — | — | — | — | — |
| NTRA | $32.00B | -150.7 | 35.9% | -9.0% | -14.1% | — |
| BIIB | $25.84B | 20.0 | 2.2% | 13.1% | 7.2% | — |
| ALNY | $52.64B | 170.7 | 65.2% | 8.5% | 60.4% | — |
| INSM | $37.29B | -27.1 | 66.7% | -210.5% | -128.4% | — |
| MRNA | $11.62B | -4.1 | -39.9% | -145.2% | -31.3% | — |
| UTHR | $21.27B | 17.5 | 10.6% | 41.9% | 18.7% | 87.9% |
| BBIO | $14.90B | -20.2 | 126.3% | -146.0% | 41.2% | — |
| NBIX | $14.20B | 30.4 | 21.4% | 16.7% | 16.1% | — |
| BMRN | $11.43B | 33.0 | 12.9% | 10.8% | 5.8% | — |
Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa
Demonstração de Resultados 17
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.14B | $4.24B | $3.70B | $3.39B | $2.99B | $2.67B | $2.16B | $1.88B | $1.54B | $1.11B | $754M | $511M | |
| Cost of Revenue | $372M | $312M | $255M | $207M | $151M | $131M | $114M | $94M | $79M | $58M | $27M | $3M | |
| R&D Expense | $2.05B | $2.61B | $1.63B | $1.59B | $1.46B | $2.22B | $1.15B | $1.20B | $1.33B | $582M | $480M | $348M | |
| SG&A Expense | $1.38B | $1.24B | $1.16B | $1.00B | $740M | $517M | $469M | $434M | $366M | $303M | $197M | $166M | |
| Operating Expenses | $3.63B | $4.18B | $3.08B | $2.82B | $2.40B | $2.93B | $1.76B | $1.75B | $1.78B | $961M | $703M | $516M | |
| Operating Income | $1.51B | $61M | $621M | $579M | $586M | $-264M | $402M | $129M | $-243M | $145M | $51M | $-5M | |
| Interest Expense | · | · | $3M | $3M | $2M | $2M | $2M | $2M | $7M | $39M | $46M | $47M | |
| Interest Income | $106M | $129M | $158M | $40M | · | · | · | · | · | · | · | · | |
| Other Non-op | $25M | $13M | $14M | $-519.0K | $11M | $23M | $52M | $32M | $17M | · | · | · | |
| Pretax Income | $1.66B | $317M | $834M | $529M | $570M | $-232M | $487M | $115M | $-312M | $107M | $8M | $-49M | |
| Income Tax | $378M | $284M | $237M | $188M | $-378M | $63M | $40M | $6M | $852.0K | $3M | $1M | $-66.0K | |
| Net Income | $1.29B | $33M | $598M | $341M | $949M | $-296M | $447M | $109M | $-313M | $104M | · | · | |
| EPS (Basic) | $6.59 | $0.16 | $2.67 | $1.53 | $4.30 | $-1.36 | $2.08 | $0.52 | $-1.53 | $0.55 | $0.04 | $-0.29 | |
| EPS (Diluted) | $6.41 | $0.15 | $2.65 | $1.52 | $4.27 | $-1.36 | $2.05 | $0.51 | $-1.53 | $0.54 | $0.03 | $-0.29 | |
| Shares (Basic) | 195,204,000 | 207,110,000 | 223,628,000 | 222,004,000 | 220,428,000 | 218,073,000 | 214,913,000 | 212,383,000 | 204,580,000 | 187,873,000 | 179,601,000 | 167,947,000 | |
| Shares (Diluted) | 200,700,000 | 210,530,000 | 225,928,000 | 223,958,000 | 222,074,000 | 218,073,000 | 217,657,000 | 215,635,000 | 204,580,000 | 194,125,000 | 187,302,000 | 167,947,000 | |
| EBITDA | $1.61B | $151M | · | $647M | $644M | $-212M | $457M | $184M | $-192M | · | · | $37M |
Balanço Patrimonial 27
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.10B | $1.69B | $3.21B | $2.95B | $2.06B | $1.51B | $1.83B | $1.16B | $900M | $652M | $521M | $452M | |
| Short-term Investments | · | · | · | · | · | · | $285M | $274M | $270M | $156M | $186M | $148M | |
| Inventory | $101M | $59M | $63M | $42M | $28M | $16M | $11M | $7M | $6M | $4M | $2M | $358.0K | |
| Prepaid Expense | $318M | $169M | $183M | $167M | $126M | $60M | $44M | $79M | $62M | $33M | $18M | $21M | |
| Current Assets | $5.02B | $3.24B | $4.65B | $4.09B | $3.12B | $2.36B | $2.48B | $1.83B | $1.50B | $994M | $842M | $680M | |
| PP&E (Net) | $731M | $763M | $752M | $739M | $724M | $560M | $378M | $320M | $260M | $168M | $86M | $82M | |
| PP&E (Gross) | $1.11B | $1.09B | $1.02B | $952M | $900M | $704M | $499M | $423M | $334M | $219M | $131M | $116M | |
| Accum. Depreciation | $375M | $328M | $270M | $213M | $176M | $144M | $122M | $103M | $75M | $52M | $45M | $35M | |
| Goodwill | $133M | $156M | $156M | $156M | $156M | $156M | $156M | $156M | $156M | $156M | · | · | |
| Intangibles | · | · | · | · | · | · | · | · | $237M | $270M | $12M | $2M | |
| Other Non-current Assets | $18M | $11M | $52M | $25M | $37M | $39M | $49M | $19M | $2M | $3M | $12M | · | |
| Total Assets | $6.96B | $5.44B | $6.78B | $5.84B | $4.93B | $3.56B | $3.43B | $2.65B | $2.30B | $1.64B | $1.01B | $796M | |
| Accounts Payable | $210M | $197M | $110M | $278M | $172M | $99M | $84M | $104M | $68M | $76M | $30M | $24M | |
| Accrued Liabilities | $1.03B | $1.21B | $936M | $701M | $534M | $378M | $286M | $229M | $199M | $127M | $87M | $62M | |
| Current Liabilities | $1.52B | $1.64B | $1.24B | $1.16B | $854M | $631M | $513M | $425M | $375M | $274M | $168M | $221M | |
| Capital Leases | $15M | $17M | $14M | $14M | $16M | $14M | $12M | · | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | · | · | $20M | |
| Other Non-current Liabilities | $165M | $168M | $149M | $99M | $70M | $58M | $40M | $22M | $20M | $13M | $48M | $55M | |
| Total Liabilities | $1.79B | $2.00B | $1.59B | $1.47B | $1.16B | $950M | $828M | $720M | $672M | $1.22B | $836M | $878M | |
| Long-term Debt | · | · | · | · | · | · | · | $19.09B | $27M | $750M | $750M | $841M | |
| Total Debt | · | · | · | · | · | · | · | · | · | · | · | $689M | |
| Common Stock | $198.0K | $193.0K | $224.0K | $223.0K | $221.0K | $219.0K | $216.0K | $213.0K | $211.0K | $189.0K | $187.0K | $171.0K | |
| Retained Earnings | $214M | $-1.07B | $160M | $-437M | $-778M | $-1.73B | $-1.43B | $-1.88B | $-1.99B | $-1.67B | $-1.78B | $-1.79B | |
| AOCI | $25M | $-13M | $13M | $15M | $-19M | $-15M | $-16M | $-10M | $-7M | $-3M | $-809.0K | $2M | |
| Stockholders' Equity | $5.17B | $3.45B | $5.19B | $4.37B | $3.77B | $2.61B | $2.60B | $1.93B | $1.63B | $419M | $171M | $-82M | |
| Liabilities + Equity | $6.96B | $5.44B | $6.78B | $5.84B | $4.93B | $3.56B | $3.43B | $2.65B | $2.30B | $1.64B | $1.01B | $796M | |
| Shares Outstanding | 198,460,009 | 193,434,305 | 224,286,862 | 222,746,719 | 221,084,433 | 219,489,329 | 216,177,830 | 213,274,660 | 211,262,906 | 188,848,752 | 186,650,249 | 170,876,619 |
Fluxo de Caixa 16
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $93M | $89M | $83M | $68M | $58M | $52M | $55M | $55M | $52M | $58M | $45M | $41M | |
| Stock-based Comp | $249M | $266M | $216M | $188M | $183M | $178M | $167M | $148M | $133M | $96M | $70M | $62M | |
| Deferred Tax | $248M | $-86M | $-159M | $57M | $-466M | $-350.0K | $-377.0K | $-459.0K | $-805.0K | · | · | · | |
| Amort. of Intangibles | $27M | $24M | $22M | $22M | $22M | $22M | $22M | $22M | $22M | $13M | · | · | |
| Other Non-cash | $-463M | $33M | · | $316M | $26M | $-58M | $43M | $24M | · | · | · | · | |
| Operating Cash Flow | $1.41B | $335M | $496M | $970M | $749M | $-125M | $711M | $336M | $-93M | $305M | $89M | $26M | |
| CapEx | · | · | · | $78M | $181M | $187M | $78M | $73M | $111M | $120M | $26M | $28M | |
| Investing Cash Flow | $-103M | $158M | $-208M | $-79M | $-208M | $-269M | $-87M | $-86M | $-350M | $-232M | $-105M | · | |
| Stock Issued | · | · | · | · | · | · | · | · | $649M | · | · | · | |
| Stock Repurchased | $0 | $2.00B | $0 | $0 | · | · | · | · | · | · | · | · | |
| Net Stock Activity | $0 | $-2.00B | · | · | · | · | · | · | $649M | · | · | · | |
| Financing Cash Flow | $101M | $-2.02B | $-20M | $-794.0K | $6M | $72M | $46M | $15M | $690M | $45M | $85M | · | |
| Net Change in Cash | $1.41B | $-1.53B | $262M | $894M | $544M | $-319M | $669M | $265M | $247M | $117M | $69M | $-19M | |
| Taxes Paid | $212M | $373M | $378M | $136M | $68M | $71M | $34M | $5M | $6M | $927.0K | · | · | |
| Free Cash Flow | · | · | · | $892M | $568M | $-312M | $633M | $263M | $-204M | · | · | $-2M | |
| Levered FCF | · | · | · | $890M | $565M | $-315M | $631M | $261M | $-211M | · | · | $-48M |
Lucratividade 7
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 29.5% | 1.5% | · | 17.1% | 19.6% | -9.9% | 18.6% | 6.9% | -15.9% | · | · | -0.94% | |
| Net Margin | 25.0% | 0.77% | · | 10.0% | 31.8% | -11.1% | 20.7% | 5.8% | · | · | · | · | |
| Pretax Margin | 32.4% | 7.5% | · | 15.6% | 19.1% | -8.7% | 22.6% | 6.1% | -20.3% | · | · | -9.5% | |
| EBITDA Margin | 31.3% | 3.5% | · | 19.1% | 21.6% | -7.9% | 21.1% | 9.8% | -12.5% | · | · | 7.2% | |
| ROA | 20.8% | 0.53% | · | 6.3% | 22.3% | -8.5% | 14.7% | 4.4% | · | · | · | · | |
| ROE | 27.6% | 0.99% | · | 7.9% | 27.4% | -11.8% | 17.8% | 5.9% | · | · | · | · | |
| ROIC | 22.7% | 0.18% | · | 8.5% | 25.8% | -12.9% | 14.2% | 6.4% | -15.0% | · | · | -0.79% |
Liquidez e Solvência 4
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.3 | 2.0 | · | 3.5 | 3.7 | 3.7 | 4.8 | 4.3 | 4.0 | · | · | 3.2 | |
| Quick Ratio | 2.0 | 1.0 | · | 2.6 | 2.4 | 2.4 | 4.1 | 3.4 | 3.1 | · | · | 2.7 | |
| Debt / Equity | · | · | · | · | · | · | · | · | · | · | · | -8.4 | |
| Interest Coverage | · | · | · | 217.3 | 307.0 | -121.3 | 216.7 | 83.7 | -35.3 | · | · | -0.1 |
Eficiência 2
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.8 | 0.7 | · | 0.6 | 0.7 | 0.8 | 0.7 | 0.8 | 0.8 | · | · | 0.7 | |
| Inventory Turnover | 4.7 | 5.1 | · | 5.9 | 6.8 | 9.4 | 12.4 | 14.0 | 15.0 | · | · | 7.9 |
Taxas de Crescimento 7
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 21.2% | 14.8% | 8.9% | 13.7% | 12.0% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 14.8% | 12.4% | 11.5% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 14.0% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 4173.3% | -94.3% | 74.3% | -64.4% | · | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 61.6% | -67.2% | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 3845.0% | -94.5% | 75.4% | -64.1% | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 55.7% | -67.5% | · | · | · | · | · | · | · | · | · | · |
Avaliação (TTM) 10
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $5.14B | $4.24B | $3.70B | $3.39B | $2.99B | $2.67B | $2.16B | $1.88B | $1.54B | $1.11B | $754M | $511M | |
| Net Income TTM | $1.29B | $33M | $598M | $341M | $949M | $-296M | $447M | $109M | $-313M | $104M | · | · | |
| Market Cap | $19.60B | $13.36B | · | $17.89B | $16.23B | $19.09B | $18.88B | $13.56B | $20.01B | · | · | · | |
| P/E | 15.4 | 460.5 | 23.7 | 52.8 | 17.2 | -64.0 | 42.6 | 124.7 | -61.9 | 185.7 | 3615.0 | -252.1 | |
| P/S | 3.8 | 3.2 | · | 5.3 | 5.4 | 7.2 | 8.7 | 7.2 | 13.0 | · | · | · | |
| P/B | 3.8 | 3.9 | · | 4.1 | 4.3 | 7.3 | 7.3 | 7.0 | 12.3 | · | · | · | |
| P / Tangible Book | 3.9 | 4.1 | 2.8 | 4.2 | 4.5 | 7.8 | · | · | · | · | · | · | |
| P / Cash Flow | 13.9 | 39.8 | · | 18.4 | 21.7 | -153.2 | 26.6 | 40.3 | -215.2 | · | · | · | |
| P / FCF | · | · | · | 20.1 | 28.5 | -61.2 | 29.8 | 51.6 | -98.1 | · | · | · | |
| Earnings Yield | 6.5% | 0.22% | 4.2% | 1.9% | 5.8% | -1.6% | 2.4% | 0.80% | -1.6% | 0.54% | 0.03% | -0.40% |
Demonstração de Resultados 17
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.67B | $1.27B | $1.51B | $1.37B | $1.22B | $1.05B | $1.18B | $1.14B | $1.04B | $881M | $1.01B | $919M | $955M | $809M | $927M | $823M | |
| Cost of Revenue | $105M | $105M | $121M | $99M | $79M | $73M | $88M | $86M | $77M | $61M | $70M | $60M | $68M | $57M | $59M | $55M | |
| R&D Expense | $517M | $516M | $611M | $507M | $495M | $437M | $466M | $573M | $1.14B | $429M | $444M | $376M | $401M | $407M | $501M | $384M | |
| SG&A Expense | $352M | $328M | $390M | $329M | $331M | $326M | $327M | $309M | $306M | $300M | $288M | $268M | $284M | $316M | $273M | $266M | |
| Operating Expenses | $976M | $972M | $1.17B | $922M | $685M | $848M | $877M | $992M | $1.52B | $789M | $826M | $704M | $761M | $784M | $857M | $685M | |
| Operating Income | $698M | $301M | $336M | $444M | $530M | $205M | $302M | $146M | $-478M | $92M | $187M | $215M | $194M | $25M | $70M | $138M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $430.0K | · | $623.0K | $655.0K | $469.0K | · | $641.0K | |
| Interest Income | $38M | $34M | $31M | $27M | $25M | $23M | $21M | $19M | $41M | $47M | · | · | · | · | · | · | |
| Other Non-op | $6M | $3M | $6M | $4M | $7M | $8M | $2M | $5M | $8M | $-2M | $-108M | $46M | $43M | $33M | $-14M | $12M | |
| Pretax Income | $752M | $344M | $390M | $482M | $558M | $234M | $314M | $157M | $-390M | $236M | $271M | $234M | $278M | $52M | $81M | $149M | |
| Income Tax | $166M | $40M | $91M | $58M | $153M | $76M | $113M | $50M | $55M | $67M | $70M | $63M | $74M | $30M | $52M | $36M | |
| Net Income | $586M | $303M | $299M | $424M | $405M | $158M | $201M | $106M | $-445M | $170M | $201M | $171M | $204M | $22M | $28M | $113M | |
| EPS (Basic) | $2.92 | $1.52 | $1.51 | $2.17 | $2.09 | $0.82 | $0.89 | $0.55 | $-2.04 | $0.76 | $0.90 | $0.76 | $0.91 | $0.10 | $0.12 | $0.51 | |
| EPS (Diluted) | $2.81 | $1.47 | $1.46 | $2.11 | $2.04 | $0.80 | $0.90 | $0.54 | $-2.04 | $0.75 | $0.89 | $0.76 | $0.90 | $0.10 | $0.13 | $0.50 | |
| Shares (Basic) | 200,378,000 | 199,343,000 | -388,173,000 | 195,670,000 | 193,995,000 | 193,712,000 | -428,178,000 | 192,629,000 | 218,175,000 | 224,484,000 | -446,658,000 | 224,078,000 | 223,248,000 | 222,960,000 | -443,397,000 | 222,415,000 | |
| Shares (Diluted) | 208,216,000 | 206,830,000 | -397,670,000 | 201,429,000 | 198,744,000 | 198,197,000 | -430,702,000 | 195,838,000 | 218,175,000 | 227,219,000 | -451,477,000 | 226,167,000 | 225,649,000 | 225,589,000 | -446,828,000 | 224,175,000 | |
| EBITDA | $698M | $325M | · | $444M | $530M | $228M | · | $146M | $-478M | $114M | · | $215M | $194M | $44M | · | $138M |
Balanço Patrimonial 22
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.98B | $3.46B | $3.10B | $2.46B | $1.95B | $1.94B | $1.69B | $1.30B | $987M | $3.35B | · | $3.23B | $3.13B | $2.82B | · | $2.69B | |
| Inventory | $113M | $116M | $101M | $83M | $83M | $64M | $59M | $70M | $101M | $64M | · | $57M | $36M | $41M | · | $46M | |
| Prepaid Expense | $253M | $301M | $318M | $369M | $296M | $212M | $169M | $205M | $208M | $189M | · | $172M | $167M | $194M | · | $180M | |
| Current Assets | $6.03B | $5.48B | $5.02B | $4.28B | $3.64B | $3.51B | $3.24B | $2.81B | $2.57B | $4.85B | · | $4.40B | $4.26B | $3.97B | · | $3.82B | |
| PP&E (Net) | $709M | $720M | $731M | $799M | $799M | $765M | $763M | $773M | $762M | $720M | · | $733M | $749M | $742M | · | $716M | |
| PP&E (Gross) | $1.11B | $1.11B | $1.11B | $1.16B | $1.14B | $1.11B | $1.09B | $1.09B | $1.06B | $1.00B | · | $986M | $988M | $967M | · | $918M | |
| Accum. Depreciation | $404M | $389M | $375M | $361M | $346M | $344M | $328M | $316M | $298M | $283M | · | $253M | $239M | $226M | · | $202M | |
| Goodwill | $133M | $133M | $133M | $156M | $156M | $156M | $156M | $156M | $156M | $156M | · | $156M | $156M | $156M | · | $156M | |
| Other Non-current Assets | $87M | $24M | $18M | $32M | $33M | $30M | $11M | $40M | $22M | $47M | · | $81M | $32M | $21M | · | $24M | |
| Total Assets | $7.87B | $7.34B | $6.96B | $6.33B | $5.82B | $5.75B | $5.44B | $5.01B | $4.66B | $7.14B | · | $6.39B | $6.21B | $5.80B | · | $5.51B | |
| Accounts Payable | $250M | $229M | $210M | $172M | $241M | $196M | $197M | $179M | $148M | $164M | · | $139M | $156M | $56M | · | $163M | |
| Accrued Liabilities | $870M | $1.09B | $1.03B | $948M | $857M | $1.38B | $1.21B | $1.13B | $1.03B | $1.10B | · | $821M | $811M | $825M | · | $700M | |
| Current Liabilities | $1.31B | $1.49B | $1.52B | $1.34B | $1.28B | $1.72B | $1.64B | $1.50B | $1.34B | $1.40B | · | $1.12B | $1.12B | $1.01B | · | $1.01B | |
| Capital Leases | · | · | $15M | · | · | · | $17M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $125M | $127M | $165M | $171M | $180M | $176M | $168M | $145M | $142M | $151M | · | $133M | $140M | $118M | · | $75M | |
| Total Liabilities | $1.53B | $1.72B | $1.79B | $1.68B | $1.65B | $2.08B | $2.00B | $1.84B | $1.66B | $1.74B | · | $1.46B | $1.47B | $1.34B | · | $1.28B | |
| Common Stock | $201.0K | $200.0K | $198.0K | $196.0K | $194.0K | $193.0K | $193.0K | $192.0K | $191.0K | $224.0K | · | $224.0K | $223.0K | $223.0K | · | $222.0K | |
| Retained Earnings | $1.10B | $517M | $214M | $-86M | $-510M | $-915M | $-1.07B | $-1.27B | $-1.38B | $330M | · | $-41M | $-212M | $-416M | · | $-466M | |
| AOCI | $20M | $22M | $25M | $15M | $13M | $-6M | $-13M | $16M | $-5M | $-6M | · | $23M | $27M | $21M | · | $-29M | |
| Stockholders' Equity | $6.34B | $5.62B | $5.17B | $4.65B | $4.17B | $3.67B | $3.45B | $3.17B | $3.00B | $5.39B | $5.19B | $4.93B | $4.74B | $4.46B | $4.37B | $4.23B | |
| Liabilities + Equity | $7.87B | $7.34B | $6.96B | $6.33B | $5.82B | $5.75B | $5.44B | $5.01B | $4.66B | $7.14B | · | $6.39B | $6.21B | $5.80B | · | $5.51B | |
| Shares Outstanding | 200,977,687 | 199,948,401 | 198,460,009 | 196,130,993 | 194,123,265 | 193,783,446 | 193,434,305 | 192,798,328 | 191,572,449 | 224,533,449 | · | 224,101,839 | 223,338,330 | 223,061,787 | · | 222,454,839 |
Fluxo de Caixa 10
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $26M | $24M | $24M | $24M | $23M | $22M | $23M | $23M | $22M | $22M | $22M | $21M | $20M | $19M | $18M | $17M | |
| Stock-based Comp | $67M | $64M | $62M | $62M | $65M | $61M | $72M | $78M | $57M | $60M | $60M | $48M | $55M | $53M | $53M | $45M | |
| Other Non-cash | · | $-22M | · | · | · | $25M | · | · | · | $-32M | · | · | · | $-200M | · | · | |
| Operating Cash Flow | $508M | $369M | $543M | $559M | $45M | $266M | $381M | $311M | $-576M | $219M | $148M | $148M | $307M | $-106M | $284M | $296M | |
| CapEx | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $28M | |
| Investing Cash Flow | $-52M | $-88M | $-37M | $-47M | $-19M | $1M | $-21M | $38M | $214M | $-73M | $-154M | $-17M | $-7M | $-29M | $-21M | $-28M | |
| Stock Repurchased | · | · | $0 | $0 | · | · | $0 | $103.0K | · | · | $0 | $0 | · | · | · | · | |
| Financing Cash Flow | $65M | $85M | $138M | $-13M | $-11M | $-13M | $20M | $-32M | $-2.00B | $-12M | $346.0K | $-37M | $13M | $4M | $-2M | $-14M | |
| Net Change in Cash | $521M | $363M | $643M | $500M | $13M | $254M | $384M | $317M | $-2.36B | $133M | $-14M | $96M | $310M | $-130M | $261M | $255M | |
| Taxes Paid | $15M | $-9M | $27M | $7M | $177M | $844.0K | $70M | $73M | $227M | $3M | $125M | $116M | $130M | $7M | $20M | $40M |
Lucratividade 7
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 41.7% | 23.7% | · | 32.5% | 43.6% | 19.5% | · | 12.8% | -45.8% | 10.4% | · | 23.4% | 20.3% | 3.1% | · | 16.8% | |
| Net Margin | 35.0% | 23.8% | · | 31.1% | 33.3% | 15.0% | · | 9.4% | -42.6% | 19.2% | · | 18.6% | 21.3% | 2.7% | · | 13.7% | |
| Pretax Margin | 44.9% | 27.0% | · | 35.3% | 45.9% | 22.2% | · | 13.8% | -37.3% | 26.8% | · | 25.4% | 29.1% | 6.4% | · | 18.1% | |
| EBITDA Margin | 41.7% | 25.5% | · | 32.5% | 43.6% | 21.6% | · | 12.8% | -45.8% | 12.9% | · | 23.4% | 20.3% | 5.4% | · | 16.8% | |
| ROA | 8.6% | 4.6% | · | 7.5% | 7.7% | 2.5% | · | 1.9% | -8.2% | 2.6% | · | 2.9% | 3.5% | 0.40% | · | 2.3% | |
| ROE | 11.1% | 6.5% | · | 10.8% | 11.3% | 3.5% | · | 2.6% | -11.5% | 3.4% | · | 3.7% | 4.6% | 0.52% | · | 3.1% | |
| ROIC | 8.6% | 4.7% | · | 8.4% | 9.2% | 3.8% | · | 3.1% | -18.2% | 1.2% | · | 3.2% | 3.0% | 0.23% | · | 2.5% |
Liquidez e Solvência 3
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.6 | 3.7 | · | 3.2 | 2.8 | 2.0 | · | 1.9 | 1.9 | 3.5 | · | 3.9 | 3.8 | 3.9 | · | 3.8 | |
| Quick Ratio | 3.0 | 2.3 | · | 1.8 | 1.5 | 1.1 | · | 0.9 | 0.7 | 2.4 | · | 2.9 | 2.8 | 2.8 | · | 2.7 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | 213.7 | · | 344.6 | 295.8 | 52.8 | · | 215.9 |
Eficiência 2
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | |
| Inventory Turnover | 1.1 | 1.2 | · | 1.3 | 0.9 | 1.1 | · | 1.3 | 1.1 | 1.2 | · | 1.2 | 1.5 | 1.5 | · | 1.6 |
Avaliação (TTM) 9
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $5.53B | $4.91B | · | $4.77B | $4.45B | $4.12B | · | $3.98B | $3.80B | $3.56B | · | $3.51B | $3.50B | $3.28B | · | $3.28B | |
| Net Income TTM | $1.72B | $1.29B | · | $1.09B | $225M | $-10M | · | $3M | $100M | $566M | · | $509M | $499M | $334M | · | $494M | |
| Market Cap | $22.78B | $18.82B | · | $16.63B | $13.22B | $11.73B | · | $12.74B | $11.61B | $12.79B | · | $12.95B | $13.90B | $16.12B | · | $14.82B | |
| P/E | 13.4 | 14.7 | · | 15.4 | 50.8 | 1211.0 | · | 6610.0 | 163.8 | 22.7 | · | 25.6 | 28.0 | 48.5 | · | 30.2 | |
| P/S | 4.1 | 3.8 | · | 3.5 | 3.0 | 2.9 | · | 3.2 | 3.1 | 3.6 | · | 3.7 | 4.0 | 4.9 | · | 4.5 | |
| P/B | 3.6 | 3.3 | · | 3.6 | 3.2 | 3.2 | · | 4.0 | 3.9 | 2.4 | · | 2.6 | 2.9 | 3.6 | · | 3.5 | |
| P / Tangible Book | 3.7 | 3.4 | · | 3.7 | 3.3 | 3.3 | · | 4.2 | 4.1 | 2.4 | · | 2.7 | 3.0 | 3.7 | · | 3.6 | |
| P / Cash Flow | · | 51.0 | · | · | · | 44.1 | · | · | · | 58.5 | · | · | · | -152.7 | · | · | |
| Earnings Yield | 7.4% | 6.8% | · | 6.5% | 2.0% | 0.08% | · | 0.02% | 0.61% | 4.4% | · | 3.9% | 3.6% | 2.1% | · | 3.3% |
Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos
Demonstração de Resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Receita | $5.14B | $4.24B | $3.70B | $3.39B | $2.99B |
| Margem Operacional % | 29.5% | 1.5% | — | 17.1% | 19.6% |
| Lucro líquido | $1.29B | $33M | $598M | $341M | $949M |
| EPS Diluído | $6.41 | $0.15 | $2.65 | $1.52 | $4.27 |
Balanço Patrimonial
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Índice de liquidez corrente | 3.3 | 2.0 | — | 3.5 | 3.7 |
| Índice de Liquidez Seca | 2.0 | 1.0 | — | 2.6 | 2.4 |
Fluxo de Caixa
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Fluxo de caixa livre | — | — | — | $892M | $568M |
Últimas notícias Notícias recentes mencionando esta empresa
Sinais de trading Sinais recentes de compra/venda com preço de entrada e relação risco/recompensa
Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos
📊
Escolha as métricas que importam para você — clique no ➕ ao lado de qualquer linha em Fundamentos Completos acima.
Sua seleção é salva e acompanha você em todos os tickers.
Investidores institucionais (13F) 928 declarantes · $16.2B total · Em 30 de Junho de 2026
Instituições que relatam a posse desta ação em seu Formulário 13F trimestral da SEC. Apenas posições compradas; um único declarante pode aparecer duas vezes para opções separadas. Grandes posições de compra/venda compensatórias geralmente refletem market-making ou inventário protegido, não convicção direcional.
Atividade institucional — Q2 2026 vs trimestre anterior
| Novas posições | Posições encerradas | Aumentou | Diminuído | Variação líquida de ações |
|---|---|---|---|---|
| 129 (+10 vs trimestre anterior) | 66 (-31 vs trimestre anterior) | 345 (+31 vs trimestre anterior) | 261 (-21 vs trimestre anterior) | +18.0M |
Comparado a Q1 2026. Os registros do Formulário 13F da SEC devem ser feitos em até 45 dias após o final do trimestre, mais um pequeno período de tolerância para registrantes atrasados — trimestres ainda dentro desse período são ignorados em favor do par mais recente totalmente reportado.
| Instituição | Valor | Ações | % de 13F rastreado | Tipo |
|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | $3.487.217.729 | 30.762.330 | 21,56% | Ações |
| Dodge & Cox | $1.355.482.475 | 11.957.326 | 8,38% | Ações |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.249.713.401 | 11.024.289 | 7,73% | Ações |
| STATE STREET CORP | $1.102.124.009 | 9.722.336 | 6,81% | Ações |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $883.198.076 | 7.791.091 | 5,46% | Ações |
| GEODE CAPITAL MANAGEMENT, LLC | $472.254.570 | 4.183.857 | 2,92% | Ações |
| RENAISSANCE TECHNOLOGIES LLC | $398.135.284 | 3.512.132 | 2,46% | Ações |
| WELLINGTON MANAGEMENT GROUP LLP | $384.786.803 | 3.394.379 | 2,38% | Ações |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $311.168.439 | 2.744.958 | 1,92% | Ações |
| Robeco Institutional Asset Management B.V. | $276.795.075 | 2.441.735 | 1,71% | Ações |
| TWO SIGMA INVESTMENTS, LP | $227.123.448 | 2.003.559 | 1,40% | Ações |
| DIMENSIONAL FUND ADVISORS LP | $201.199.603 | 1.774.874 | 1,24% | Ações |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $191.845.249 | 1.692.354 | 1,19% | Ações |
| FIRST TRUST ADVISORS LP | $180.015.041 | 1.587.996 | 1,11% | Ações |
| VICTORY CAPITAL MANAGEMENT INC | $167.811.569 | 1.480.342 | 1,04% | Ações |
| Caisse de depot et placement du Quebec | $155.360.220 | 1.370.503 | 0,96% | Ações |
| AustralianSuper Pty Ltd | $135.634.220 | 1.196.491 | 0,84% | Ações |
| NORGES BANK | $126.861.970 | 1.119.107 | 0,78% | Ações |
| FMR LLC | $116.316.542 | 1.026.081 | 0,72% | Ações |
| ROYAL BANK OF CANADA | $115.263.000 | 1.016.790 | 0,71% | Ações |
| VANGUARD FIDUCIARY TRUST CO | $106.959.694 | 943.540 | 0,66% | Ações |
| ARMISTICE CAPITAL, LLC | $102.024.567 | 900.005 | 0,63% | Ações |
| PANAGORA ASSET MANAGEMENT INC | $99.970.937 | 881.889 | 0,62% | Ações |
| GOLDMAN SACHS GROUP INC | $97.568.045 | 860.692 | 0,60% | Ações |
| VANGUARD GROUP INC | $91.396.622 | 925.348 | 0,56% | Ações |
| Sound Shore Management Inc /CT/ | $85.895.479 | 757.723 | 0,53% | Ações |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $82.953.901 | 731.774 | 0,51% | Ações |
| Gotham Asset Management, LLC | $81.567.621 | 719.545 | 0,50% | Ações |
| Pictet Asset Management Holding SA | $81.315.880 | 713.354 | 0,50% | Ações |
| VIRGINIA RETIREMENT SYSTEMS ET Al | $75.887.460 | 768.325 | 0,47% | Ações |
| MACKENZIE FINANCIAL CORP | $71.967.956 | 634.862 | 0,44% | Ações |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $65.633.852 | 578.986 | 0,41% | Ações |
| Legal & General Group Plc | $63.331.398 | 558.675 | 0,39% | Ações |
| SEB Asset Management AB | $63.307.742 | 558.467 | 0,39% | Ações |
| GLENMEDE TRUST CO NA | $60.308.653 | 532.010 | 0,37% | Ações |
| Woodline Partners LP | $58.118.538 | 512.690 | 0,36% | Ações |
| MARSHALL WACE, LLP | $56.804.130 | 501.095 | 0,35% | Ações |
| BNP PARIBAS FINANCIAL MARKETS | $56.779.870 | 500.881 | 0,35% | Ações |
| WORLDQUANT MILLENNIUM ADVISORS LLC | $55.184.782 | 486.810 | 0,34% | Ações |
| BlackRock, Inc. | $54.675.002 | 482.313 | 0,34% | Ações |
| Swiss National Bank | $54.058.437 | 476.874 | 0,33% | Ações |
| Glenmede Investment Management, LP | $53.145.338 | 626.640 | 0,33% | Ações |
| Vinva Investment Management Ltd | $53.069.578 | 462.843 | 0,33% | Ações |
| CANADA PENSION PLAN INVESTMENT BOARD | $50.161.800 | 442.500 | 0,31% | Ações |
| California Public Employees Retirement System | $48.730.290 | 429.872 | 0,30% | Ações |
| RHUMBLINE ADVISERS | $48.578.406 | 428.533 | 0,30% | Ações |
| IEQ CAPITAL, LLC | $48.141.997 | 424.682 | 0,30% | Ações |
| Mitsubishi UFJ Asset Management Co., Ltd. | $46.733.567 | 412.258 | 0,29% | Ações |
| Sumitomo Mitsui Trust Group, Inc. | $44.634.140 | 393.738 | 0,28% | Ações |
| Vanguard Global Advisers, LLC | $43.080.994 | 380.037 | 0,27% | Ações |
| MORGAN STANLEY | $42.894.746 | 378.394 | 0,27% | Ações |
| Swedbank AB | $42.100.431 | 371.387 | 0,26% | Ações |
| AMERICAN CENTURY COMPANIES INC | $39.177.443 | 345.602 | 0,24% | Ações |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $38.530.157 | 339.892 | 0,24% | Ações |
| CAPITAL FUND MANAGEMENT S.A. | $38.125.008 | 336.318 | 0,24% | Ações |
| VANGUARD ASSET MANAGEMENT, Ltd | $37.984.782 | 335.081 | 0,23% | Ações |
| Grantham, Mayo, Van Otterloo & Co. LLC | $36.114.682 | 318.584 | 0,22% | Ações |
| Aware Super Pty Ltd as trustee of Aware Super | $34.779.982 | 306.810 | 0,21% | Ações |
| Arbejdsmarkedets Tillaegspension | $33.826.624 | 298.400 | 0,21% | Ações |
| BARCLAYS PLC | $32.329.252 | 285.191 | 0,20% | Ações |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $32.129.398 | 283.428 | 0,20% | Ações |
| Ensign Peak Advisors, Inc | $30.602.212 | 269.956 | 0,19% | Ações |
| Illinois Municipal Retirement Fund | $29.511.916 | 260.338 | 0,18% | Ações |
| WINTON GROUP Ltd | $28.839.691 | 254.408 | 0,18% | Ações |
| PFA Pension, Forsikringsaktieselskab | $28.624.373 | 252.509 | 0,18% | Ações |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $26.717.581 | 236.172 | 0,17% | Ações |
| TODD ASSET MANAGEMENT LLC | $26.568.750 | 234.375 | 0,16% | Ações |
| BANK OF AMERICA CORP /DE/ | $25.899.133 | 228.468 | 0,16% | Ações |
| PRINCIPAL FINANCIAL GROUP INC | $24.961.078 | 220.193 | 0,15% | Ações |
| Andra AP-fonden | $24.381.598 | 259.048 | 0,15% | Ações |
| Quantinno Capital Management LP | $24.309.704 | 214.446 | 0,15% | Ações |
| DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | $24.037.194 | 212.043 | 0,15% | Ações |
| Baird Financial Group, Inc. | $23.690.539 | 208.985 | 0,15% | Ações |
| Eurizon Capital SGR S.p.A. | $23.250.000 | 204.785 | 0,14% | Ações |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $22.709.932 | 241.287 | 0,14% | Ações |
| Korea Investment CORP | $22.164.827 | 195.526 | 0,14% | Ações |
| KLP KAPITALFORVALTNING AS | $21.799.695 | 192.305 | 0,13% | Ações |
| Catalio Capital Management, LP | $21.722.837 | 191.627 | 0,13% | Ações |
| PRUDENTIAL FINANCIAL INC | $21.650.853 | 190.992 | 0,13% | Ações |
| ROYAL LONDON ASSET MANAGEMENT LTD | $21.575.016 | 190.323 | 0,13% | Ações |
| Fideuram Asset Management (Ireland) dac | $20.928.446 | 213.883 | 0,13% | Ações |
| FJARDE AP-FONDEN /FOURTH SWEDISH NATIONAL PENSION FUND | $20.401.285 | 179.969 | 0,13% | Ações |
| APG Asset Management N.V. | $20.193.310 | 203.661 | 0,12% | Ações |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $19.499.734 | 172.016 | 0,12% | Ações |
| SECTOR GAMMA AS | $19.356.560 | 170.753 | 0,12% | Ações |
| MARTINGALE ASSET MANAGEMENT L P | $19.137.209 | 168.818 | 0,12% | Ações |
| CWM, LLC | $19.084.906 | 202.772 | 0,12% | Ações |
| Bridgewater Associates, LP | $19.073.160 | 168.253 | 0,12% | Ações |
| ALLIANCEBERNSTEIN L.P. | $18.937.791 | 201.209 | 0,12% | Ações |
| Candriam S.C.A. | $18.443.367 | 162.854 | 0,11% | Ações |
| Focus Partners Wealth | $18.354.947 | 161.917 | 0,11% | Ações |
| DNB Asset Management AS | $18.304.239 | 161.470 | 0,11% | Ações |
| SEI INVESTMENTS CO | $18.019.140 | 158.955 | 0,11% | Ações |
| Trails Edge Capital Partners, LP | $17.570.800 | 155.000 | 0,11% | Ações |
| Jefferies Financial Group Inc. | $17.321.295 | 152.799 | 0,11% | Ações |
| SAWGRASS ASSET MANAGEMENT LLC | $17.250.671 | 152.176 | 0,11% | Ações |
| Mitsubishi UFJ Trust & Banking Corp | $17.215.756 | 151.868 | 0,11% | Ações |
| AVIVA PLC | $16.882.025 | 148.924 | 0,10% | Ações |
| Driehaus Capital Management LLC | $16.794.397 | 148.151 | 0,10% | Ações |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $16.681.037 | 147.151 | 0,10% | Ações |
Executivos da empresa 61 insiders · 32 diretores · 17 conselheiros
| Investidor com informação privilegiada | Função | Última atividade | Ações detidas | Compras 12m | Vendas 12m | Líquido 12m |
|---|---|---|---|---|---|---|
| William Meury | Chief Executive Officer | 16 de Julho de 2026 A | 183.129 | 0 | 0 | $0 |
| Herve Hoppenot | Special Advisor to the CEO | 15 de Julho de 2025 F | 517.146 | 0 | 0 | $0 |
| Christiana Stamoulis | EVP & Chief Financial Officer | 15 de Julho de 2025 A | 125.759 | 0 | 0 | $0 |
| David W Gryska | Executive Vice President, CFO | 16 de Julho de 2018 F | 10.235 | 0 | 0 | $0 |
| David C Hastings | Chief Financial Officer | 5 de Junho de 2014 M | 8.500 | 0 | 0 | $0 |
| Lee Heeson | EVP, Head of Incyte Intl | 23 de Julho de 2026 A | 32.778 | 0 | 0 | $0 |
| Michael James Morrissey | EVP, Head of Tech. Operations | 23 de Julho de 2026 A | 81.515 | 0 | 0 | $0 |
| Richard A. Hoffman | EVP & General Counsel | 16 de Julho de 2026 A | 16.861 | 0 | 0 | $0 |
| David H Gardner | EVP, Chief Strategy Officer | 16 de Julho de 2026 A | 16.824 | 0 | 0 | $0 |
| Ramitpal K Basi | EVP, Human Resources | 16 de Julho de 2026 A | 11.497 | 0 | 0 | $0 |
| Mohamed Khairie Issa | EVP, Head of U.S. Commercial | 16 de Julho de 2026 A | 71.797 | 0 | 1 | $-125.706 |
| Thomas Tray | Principal Accounting Officer | 16 de Julho de 2026 A | 21.699 | 0 | 1 | $-263.900 |
| Steven H Stein | CMO & Head of Late-Stage Dev. | 16 de Julho de 2026 A | 30.916 | 0 | 2 | $-3.407.541 |
| Sheila A. Denton | EVP & General Counsel | 15 de Agosto de 2025 M | 33.200 | 0 | 1 | $-24.046 |
| Vijay K Iyengar | EVP, GMAPPS | 16 de Julho de 2025 S | 40.540 | 0 | 0 | $0 |
| Barry P Flannelly | EVP & General Manager US | 16 de Julho de 2025 S | 35.149 | 0 | 0 | $0 |
| Matteo Trotta | EVP, GM, Dermatology US | 15 de Julho de 2025 A | 15.016 | 0 | 0 | $0 |
| Paula J Swain | EVP, Human Resources | 15 de Julho de 2025 A | 106.482 | 0 | 0 | $0 |
| Jonathan Elliott Dickinson | EVP, General Manager, Europe | 12 de Setembro de 2024 S | 36.390 | 0 | 0 | $0 |
| Dashyant Dhanak | EVP & Chief Scientific Officer | 14 de Julho de 2023 A | 58.968 | 0 | 0 | $0 |
| Maria E Pasquale | EVP & General Counsel | 14 de Julho de 2023 A | 69.724 | 0 | 0 | $0 |
| Paul Trower | Principal Accounting Officer | 19 de Janeiro de 2022 A | 32.268 | 0 | 0 | $0 |
| Yao Wenqing | EVP, Head of Discovery Chem | 2 de Julho de 2021 A | 98.575 | 0 | 0 | $0 |
| Reid M Huber | EVP, Chief Scientific Officer | 16 de Julho de 2018 F | 34.571 | 0 | 0 | $0 |
| Eric H. Siegel | EVP, General Counsel | 13 de Setembro de 2017 F | 21.053 | 0 | 0 | $0 |
| Richard S Levy | EVP, Chief Drug Dev Officer | 6 de Janeiro de 2016 M | 16.926 | 0 | 0 | $0 |
| James M Daly | EVP, Chief Commercial Officer | 23 de Junho de 2015 M | 3.521 | 0 | 0 | $0 |
| Patricia S Andrews | Chief Commercial Officer | 19 de Janeiro de 2012 A | — | 0 | 0 | $0 |
| Patricia A Schreck | EVP, General Counsel | 10 de Maio de 2011 M | 4.500 | 0 | 0 | $0 |
| Brian W Metcalf | Chief Drug Discovery Scientist | 11 de Abril de 2011 M | 66.504 | 0 | 0 | $0 |
| Steven M. Friedman | EVP, Biology & Preclinical Dev | 18 de Maio de 2010 A | 38.137 | 0 | 0 | $0 |
| John A Keller | Chief Business Officer | 8 de Fevereiro de 2008 A | — | 0 | 0 | $0 |
| Paul J Clancy | Conselheiro | 30 de Junho de 2026 A | 25.635 | 0 | 0 | $0 |
| Edmund Harrigan | Conselheiro | 30 de Junho de 2026 A | 23.019 | 0 | 0 | $0 |
| Katherine A High | Conselheiro | 8 de Junho de 2026 A | 14.983 | 0 | 0 | $0 |
| Jacqualyn A Fouse | Conselheiro | 8 de Junho de 2026 A | 20.968 | 0 | 0 | $0 |
| Jean Jacques Bienaime | Conselheiro | 8 de Junho de 2026 A | 24.424 | 0 | 0 | $0 |
| Otis W Brawley | Conselheiro | 8 de Junho de 2026 A | 12.894 | 0 | 0 | $0 |
| Susanne Schaffert | Conselheiro | 12 de Junho de 2024 A | 5.720 | 0 | 0 | $0 |
| Wendy L Dixon | Conselheiro | 31 de Março de 2022 A | 17.768 | 0 | 0 | $0 |
| Paul A Friedman, M.D. | Conselheiro | 26 de Maio de 2020 A | 256.813 | 0 | 0 | $0 |
| Paul A Brooke | Conselheiro | 31 de Março de 2020 A | 221.911 | 0 | 0 | $0 |
| Barry A Ariko | Conselheiro | 12 de Março de 2015 M | 45.834 | 0 | 0 | $0 |
| Richard U De Schutter | Conselheiro | 5 de Março de 2015 M | 92.290 | 0 | 0 | $0 |
| Roy A Whitfield | Conselheiro | 17 de Dezembro de 2013 M | 666.082 | 0 | 0 | $0 |
| John F Niblack | Conselheiro | 20 de Maio de 2011 A | — | 0 | 0 | $0 |
| Fred B Craves | Conselheiro | 1 de Junho de 2005 A | 196.793 | 0 | 0 | $0 |
| INCYTE CORP | Detentor de 10% | 25 de Janeiro de 2021 A | 3.550.000 | 0 | 0 | $0 |
| DAMIAL FOUNDATION INC | Detentor de 10% | 11 de Fevereiro de 2004 S | — | 0 | 0 | $0 |
| Bonnie J Tisch | Detentor de 10% | 14 de Janeiro de 2004 S | — | 0 | 0 | $0 |
Executivos de declarações SEC Formulário 3/4/5; líquido = apenas P/V de mercado aberto
Ativistas e proprietários de 5%+ 7 participações
Investidores que apresentaram o Schedule 13D da SEC — propriedade benéfica acima de 5% com a intenção de influenciar o emissor (participações ativistas, campanhas no conselho, M&A). Cada linha mostra o estado mais recente conhecido da posição desse declarante.
| Declarante | Declarado | Participação | Status | Propósito | Declaração |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, Felix J. Baker, FBB2, LLC, FBB3 LLC, FBB Associates ×21 declarações | 11 de Maio de 2026 | 15,60% | Emenda | Investimento passivo | SEC |
| Incyte Corporation ×3 declarações | 14 de Agosto de 2023 | — | Declaração inicial | Estrutura de capital | SEC |
| Baker Bros. Advisors, LLC, Julian C. Baker, Felix J. Baker, FBB2, LLC, FBB Associates ×2 declarações | 15 de Junho de 2012 | — | Declaração inicial | — | SEC |
| Julian C. Baker, Felix J. Baker ×12 declarações | 1 de Outubro de 2009 | — | Declaração inicial | — | SEC |
| Pessoa de relato não divulgada, Pessoa de relato não divulgada, Pessoa de relato não divulgada, Pessoa de relato não divulgada | 25 de Fevereiro de 2004 | — | Declaração inicial | — | SEC |
| Pessoa de relato não divulgada, Pessoa de relato não divulgada, Pessoa de relato não divulgada, Pessoa de relato não divulgada, Pessoa de relato não divulgada, Pessoa de relato não divulgada | 29 de Setembro de 2003 | — | Declaração inicial | — | SEC |
| Pessoa de relato não divulgada, Pessoa de relato não divulgada, Pessoa de relato não divulgada, Pessoa de relato não divulgada, Pessoa de relato não divulgada, Pessoa de relato não divulgada | 15 de Agosto de 2002 | — | Declaração inicial | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Participação em ETFs Detido por 214 ETFs
O peso reflete apenas participações diretas em ações (N-PORT); fundos alavancados ou baseados em derivativos podem deter exposição adicional a swaps não mostrada.
| Fundo | Peso | Unidades | Em | Fonte |
|---|---|---|---|---|
| IDNA · iShares Trust | 4,05% | 67.570 SH | 8 de Agosto de 2026 | Diário |
| BRNY · EA Series Trust | 3,64% | 211.562 NS | 30 de Abril de 2026 | N-PORT |
| PBE · Invesco Exchange-Traded Fund Trust | 2,97% | 89.311 SH | 8 de Agosto de 2026 | Diário |
| BUL · Pacer Funds Trust | 2,38% | 31.787 NS | 30 de Abril de 2026 | N-PORT |
| SAWG · ETF Series Solutions | 2,36% | 624 NS | 30 de Abril de 2026 | N-PORT |
| UPGD · Invesco Exchange-Traded Fund Trust | 2,32% | 23.365 SH | 8 de Agosto de 2026 | Diário |
| FXH · First Trust Exchange-Traded AlphaDE… | 2,19% | 201.047 NS | 30 de Abril de 2026 | N-PORT |
| FGSI · First Trust Exchange-Traded Fund IV | 1,98% | 623 NS | 30 de Abril de 2026 | N-PORT |
| SMRI · EA Series Trust | 1,96% | 111.283 NS | 30 de Abril de 2026 | N-PORT |
| IBB · iShares Trust | 1,81% | 1.453.479 SH | 8 de Agosto de 2026 | Diário |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1,78% | 9.967 NS | 30 de Abril de 2026 | N-PORT |
| RPG · Invesco Exchange-Traded Fund Trust | 1,75% | 293.364 SH | 8 de Agosto de 2026 | Diário |
| SPGP · Invesco Exchange-Traded Fund Trust | 1,75% | 337.040 SH | 8 de Agosto de 2026 | Diário |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,73% | 112.472 SH | 8 de Agosto de 2026 | Diário |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 1,64% | 10.873 SH | 8 de Agosto de 2026 | Diário |
| BBP · ETFis Series Trust I | 1,59% | 9.918 NS | 30 de Abril de 2026 | N-PORT |
| ABOT · Abacus FCF ETF Trust | 1,59% | 736 NS | 30 de Abril de 2026 | N-PORT |
| CALF · Pacer Funds Trust | 1,55% | 561.166 NS | 30 de Abril de 2026 | N-PORT |
| NUMG · Nushares ETF Trust | 1,44% | 53.580 NS | 30 de Abril de 2026 | N-PORT |
| AGNG · Global X Funds | 1,36% | 11.515 NS | 31 de Maio de 2026 | N-PORT |
| COWG · Pacer Funds Trust | 1,21% | 275.493 NS | 30 de Abril de 2026 | N-PORT |
| FLOW · Global X Funds | 1,20% | 3.543 NS | 31 de Maio de 2026 | N-PORT |
| QQQJ · Invesco Exchange-Traded Fund Trust … | 1,16% | 113.960 SH | 8 de Agosto de 2026 | Diário |
| GURU · Global X Funds | 1,01% | 6.203 NS | 30 de Abril de 2026 | N-PORT |
| BIB · ProShares Trust | 0,97% | 7.359 NS | 31 de Maio de 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,94% | 51.287 NS | 30 de Abril de 2026 | N-PORT |
| TMFX · RBB Fund, Inc. | 0,94% | 3.113 NS | 31 de Maio de 2026 | N-PORT |
| OASC · Unified Series Trust | 0,91% | 7.915 NS | 31 de Maio de 2026 | N-PORT |
| LSVD · ADVISORS' INNER CIRCLE FUND | 0,89% | 56.482 NS | 30 de Abril de 2026 | N-PORT |
| ROE · EA Series Trust | 0,87% | 23.347 NS | 29 de Maio de 2026 | N-PORT |
| JMID · Janus Detroit Street Trust | 0,83% | 1.595 NS | 30 de Abril de 2026 | N-PORT |
| SPVM · Invesco Exchange-Traded Fund Trust | 0,80% | 8.654 SH | 8 de Agosto de 2026 | Diário |
| JOET · Virtus ETF Trust II | 0,79% | 19.541 NS | 30 de Abril de 2026 | N-PORT |
| INFO · Harbor ETF Trust | 0,75% | 61.119 NS | 30 de Abril de 2026 | N-PORT |
| CLSE · Trust for Professional Managers | 0,71% | 45.326 NS | 31 de Maio de 2026 | N-PORT |
| SDG · iShares Trust | 0,70% | 10.188 SH | 8 de Agosto de 2026 | Diário |
| FTC · First Trust Exchange-Traded AlphaDE… | 0,64% | 85.796 NS | 30 de Abril de 2026 | N-PORT |
| QGRO · AMERICAN CENTURY ETF TRUST | 0,64% | 146.423 NS | 31 de Maio de 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,53% | 2.249.253 SH | 8 de Agosto de 2026 | Diário |
| EBI · RBB Fund Trust | 0,52% | 35.279 NS | 31 de Maio de 2026 | N-PORT |
| ESMV · iShares Trust | 0,51% | 339 SH | 8 de Agosto de 2026 | Diário |
| TECB · iShares Trust | 0,48% | 19.516 SH | 8 de Agosto de 2026 | Diário |
| AFMC · First Trust Exchange-Traded Fund VI… | 0,48% | 7.994 NS | 31 de Maio de 2026 | N-PORT |
| VFQY · VANGUARD WELLINGTON FUND | 0,46% | 19.147 SH | 8 de Agosto de 2026 | Diário |
| USMV · iShares Trust | 0,45% | 918.818 SH | 8 de Agosto de 2026 | Diário |
| AFLG · First Trust Exchange-Traded Fund VI… | 0,45% | 29.860 NS | 31 de Maio de 2026 | N-PORT |
| FLCV · Federated Hermes ETF Trust | 0,44% | 4.411 NS | 31 de Maio de 2026 | N-PORT |
| COWZ · Pacer Funds Trust | 0,44% | 832.413 NS | 30 de Abril de 2026 | N-PORT |
| QQWZ · Pacer Funds Trust | 0,43% | 2.130 NS | 30 de Abril de 2026 | N-PORT |
| HQGO · Lattice Strategies Trust | 0,42% | 2.110 NS | 30 de Abril de 2026 | N-PORT |